# Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

> **NCT03703375** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 93 (actual)

## Conditions studied

- Lymphoma, T-Cell

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Romidepsin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03703375
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-06
- **Primary completion:** 2021-02-10
- **Final completion:** 2026-03-31
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703375, "Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03703375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*